Fieldview Capital Management LLC Invests $2.10 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Fieldview Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,665 shares of the biotechnology company’s stock, valued at approximately $2,102,000.

Other large investors have also modified their holdings of the company. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $32,000. WPG Advisers LLC increased its position in shares of Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 431 shares during the period. Finally, Hantz Financial Services Inc. increased its position in shares of Arrowhead Pharmaceuticals by 177.1% during the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 471 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of recent research reports. Royal Bank Of Canada upped their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. Sanford C. Bernstein upped their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. initiated coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,065 shares of company stock valued at $1,912,662 over the last quarter. 3.60% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $74.52 on Friday. The firm has a market capitalization of $10.50 billion, a PE ratio of -34.66 and a beta of 1.28. The business’s fifty day moving average price is $72.46 and its 200 day moving average price is $66.71. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.75 earnings per share. On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.